Noninvasive minimal residual disease assessment in relapsed/refractory large B-cell lymphoma using digital droplet PCR
Last Updated: Wednesday, March 13, 2024
Researchers investigating a noninvasive digital droplet PCR approach using plasma-derived ctDNA for minimal residual disease assessment in relapsed/refractory DLBCL found that it is feasible, is affordable, and offers fast turnover and that it is highly predictive of outcomes in this disease state.
Advertisement
News & Literature Highlights